Application of intestinal mucosa microorganism as tumor marker and application of intestinal mucosa microorganism in preparation of colorectal cancer diagnostic product
By screening and utilizing the relative abundance differences of five microorganisms in the mucosa of CRC patients, combined with 2bRAD-M high-throughput sequencing technology, colorectal cancer markers were developed, which solved the sensitivity and specificity of colorectal cancer diagnosis in the prior art. The problem of insufficient degree has achieved efficient diagnosis and progress monitoring of colorectal cancer.
Patent Information
- Application Number
- CN202411200243.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-29
AI Technical Summary
Existing diagnostic methods for colorectal cancer are difficult to effectively utilize intestinal microbial differences, and there are lack of high sensitivity and high specificity markers to assist in the diagnosis and prediction of the clinical stage and prognosis of tumors.
By screening the relative abundance differences between five microorganisms in CRC patients and normal mucosa, random forest classifiers were used to screen out microorganisms such as Brevibacillus parabrevis, Candida glabata, Cutibacterium acnes, Acinetobacter pittii, Bacteroides uniformis, etc., combined with 2bRAD-M high-throughput Sequencing technology has developed a colorectal cancer marker to determine whether an individual is a colorectal cancer patient through DNA testing.
High sensitivity and high specificity diagnosis for colorectal cancer were achieved, with the area AUC under the ROC curve of 0.972, sensitivity of 100%, specificity of 92%, and can be used to evaluate and monitor the progress and prognosis of colorectal cancer.
Smart Images

Figure CN119040491A_ABST
Abstract
Description
Technical Field
[0001] The invention discloses intestinal mucosal microorganisms as tumor markers and application thereof in the preparation of colorectal cancer diagnosis products, belonging to the field of microorganisms and oncology. Background Art
[0002] Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death worldwide.
[0003] Studies have shown that the diversity of intestinal flora is closely related to the risk of colorectal cancer. Several international research teams have sequenced and analyzed the intestinal microbiota of colorectal cancer patients and healthy controls and found that the diversity of intestinal flora in colorectal cancer patients is low and there is a specific imbalance of microbial communities. At the same time, more and more studies are focusing on the impact of intestinal microbial metabolites on colorectal cancer. For example, some bacteria can produce volatile organic compounds (VOCs), and their concentrations are significantly different in colorectal cancer patients. In addition, intestinal microorganisms can also affect the host intestinal environment through metabolites such as short-chain fatty acids (SCFAs), thereby affecting the survival and proliferation of colorectal cancer cells. This provides a new perspective on the association between intestinal microbial metabolites and the development of colorectal cancer. Intestinal microorganisms can also regulate the host immune system, thereby affecting the development of colorectal cancer. Therefore, by adjusting the composition of the intestinal flora, it can have a positive impact on the treatment of colorectal cancer. Intestinal microorganisms may affect the response of colorectal cancer patients to treatment by affecting host metabolism, drug absorption, and immune response.
[0004] Microbiome 2bRAD sequencing (2bRAD-M) is a new sequencing method for studying bacterial communities. This method uses type IIB restriction enzyme digestion, and the resulting 2bRAD fragments are concentrated and amplified, and mapped to species-specific 2bRAD markers for microbial characterization and quantification. This method has been shown to be useful for microbiome samples with high host contamination and degradation, thereby dissecting the composition of the microbiome at the species level. Summary of the invention
[0005] The inventors found that there are significant differences in 5 types of microorganisms between the tumor mucosa of CRC patients and normal mucosa. These 5 microorganisms have a promoting or inhibiting effect on the occurrence of tumors. The relative abundance of these 5 microorganisms can provide a new method for the diagnosis of colorectal cancer and effectively predict the clinical stage and prognosis of tumor survival.
[0006] The present invention divides colorectal cancer into RCC, LCC and RC groups according to the site of occurrence, uses a random forest classifier to screen the differential microorganisms in each group, and intersects the top microorganisms in the three groups to obtain a colorectal cancer marker, which includes: Brevibacillus parabrevis, Candida glabrata, Cutibacteriumacnes, Acinetobacter pittii, Bacteroides uniformis ( Figure 1-2 ).
[0007] The present invention provides an application of a microbial composition in preparing a product for evaluating or diagnosing colorectal cancer. The microbial composition comprises Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacter pittii, and Bacteroides uniformis. The product determines the abundance information of the microbial composition in a sample by detecting DNA in the sample; and evaluates or diagnoses whether an individual is a colorectal cancer patient based on the abundance information of the microorganisms.
[0008] In one embodiment of the present invention, whether the individual to be tested is a colorectal cancer patient is determined by the following formula:
[0009]
[0010] n=1.890-1735639.917x1-318.309x2+225.541x3+0.086x4+45.642x5;
[0011] x1~x5 are the relative abundances of Brevibacillus parabrevis, Candida glabrata, Cutibacteriumacnes, Acinetobacter pittii, and Bacteroides uniformis, respectively;
[0012] When P1>0.92, the individual to be tested is determined to be a colorectal cancer patient.
[0013] In one embodiment of the present invention, the sample to be tested comes from the intestinal mucosal tissue of the patient.
[0014] In one embodiment of the present invention, the detection or assessment includes one or more of diagnostic detection, progression monitoring and prognostic detection.
[0015] In one embodiment of the present invention, the product includes but is not limited to a biochip, a kit, or a device for detecting or evaluating colorectal cancer.
[0016] In one embodiment of the present invention, the biochip comprises a solid phase carrier and oligonucleotide probes fixed in order on the solid phase carrier, and the oligonucleotide probes specifically correspond to detecting the abundance of the microorganisms Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacterpittii, and Bacteroides uniformis.
[0017] In one embodiment of the present invention, the device comprises one or more devices for specifically detecting the abundance of the microorganisms Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacterpittii, and Bacteroides uniformis.
[0018] In one embodiment of the present invention, the device comprises:
[0019] A collector, for collecting samples to be tested;
[0020] A processor processes the sample to obtain DNA from the sample;
[0021] The analyzer is used to execute the executable program, and the execution of the executable program includes completing the following steps:
[0022] (a) analyzing DNA in a sample to determine the abundance information of microorganisms in the colorectal cancer markers in the sample;
[0023] (b) Based on the microbial abundance information obtained in (a), determine whether the individual to be tested is a colorectal cancer patient.
[0024] In one embodiment of the present invention, the analysis in step (a) is performed by fluorescent quantitative PCR or high-throughput sequencing.
[0025] In one embodiment of the present invention, the high-throughput sequencing is 2bRAD-M high-throughput sequencing.
[0026] In one embodiment of the present invention, whether the individual to be tested suffers from colorectal cancer is determined by the following formula:
[0027]
[0028] n=1.890-1735639.917x1-318.309x2+225.541x3+0.086x4+45.642x5
[0029] x1~x5 are the relative abundances of Brevibacillus parabrevis, Candida glabrata, Cutibacteriumacnes, Acinetobacter pittii, and Bacteroides uniformis, respectively;
[0030] When P1>0.92, the individual to be tested is determined to be a colorectal cancer patient.
[0031] In one embodiment of the present invention, the sample comprises an isolated intestinal mucosa sample.
[0032] In one embodiment of the present invention, the kit includes any one or more of the following: PCR reaction related reagents, primers, a mucosal collector, and related reagents for extracting DNA from the mucosa.
[0033] The present invention also provides an application of a microbial composition in preparing a device for evaluating the progression of colorectal cancer. The microbial composition comprises Brevibacillus parabrevis, Candida glabrata, Cutibacteriumacnes, Acinetobacter pittii, and Bacteroides uniformis. The product determines the abundance information of the microbial composition in the sample by detecting DNA in the sample; and evaluates or diagnoses whether an individual is a colorectal cancer patient based on the abundance information of the microorganisms.
[0034] In one embodiment of the present invention, whether the individual to be tested is a colorectal cancer patient is determined by the following formula:
[0035]
[0036] n=1.890-1735639.917x1-318.309x2+225.541x3+0.086x4+45.642x5;
[0037] x1~x5 are the relative abundances of Brevibacillus parabrevis, Candida glabrata, Cutibacteriumacnes, Acinetobacter pittii, and Bacteroides uniformis, respectively;
[0038] When P1>0.92, the individual to be tested is determined to be a colorectal cancer patient.
[0039] In one embodiment of the present invention, the assessment of colorectal cancer progression includes one or more of diagnosing and detecting colorectal cancer, monitoring colorectal cancer progression, and detecting colorectal cancer prognosis. In one embodiment of the present invention, the sample to be tested is from the intestinal mucosal tissue of the patient.
[0040] Beneficial Effects
[0041] (1) The present invention screened out five microorganisms significantly associated with colorectal cancer, namely Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacterpittii, and Bacteroides uniformis. By detecting the abundance of these five microorganisms, tumors can be diagnosed. This method is convenient to detect and has high accuracy, and can be effectively applied to the evaluation and diagnosis of colorectal cancer.
[0042] (2) The present invention generates a classifier based on the relative abundance of five microorganisms in the intestinal mucosa of the human population. In the tumor group and the adjacent normal group, the area under the ROC curve (AUC) of the classifier is 0.972, the sensitivity is 100%, and the specificity is 92%. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 To screen the intestinal mucosal microorganisms of colorectal cancer in three sites using the random forest classifier method. RCC represents the right colon cancer site, LCC represents the left colon cancer site, and RC represents the rectal cancer site;
[0044] Figure 2 The common mucosal microorganisms present in the three colorectal cancer sites;
[0045] Figure 3 The relative abundance of five microorganisms in the tumor mucosa group and the normal mucosa group, p < 0.05, where Tumor and Normal represent the tumor intestinal mucosa group and the normal intestinal mucosa group, respectively;
[0046] Figure 4 The ROC curve analysis shows the performance of the combination of five intestinal mucosal microorganisms in predicting the grouping of tumor mucosa and normal mucosa, where Tumor and Normal represent the tumor intestinal mucosa group and the normal intestinal mucosa group, respectively;
[0047] Figure 5 This is a graph showing the performance of ROC curve analysis to verify the combination of five intestinal mucosal microorganisms in predicting the grouping of tumor mucosa and normal mucosa.
[0048] Figure 6 This is a graph showing the performance of ROC curve analysis to verify the intestinal mucosal microorganism Brevibacillus parabrevis in predicting the grouping of tumor mucosa and normal mucosa.
[0049] Figure 7 This is a graph showing the performance of ROC curve analysis to verify the intestinal mucosal microorganism Candida glabrata in predicting the grouping of tumor mucosa and normal mucosa.
[0050] Figure 8 This is a graph showing the performance of ROC curve analysis to verify the intestinal mucosal microorganism Cutibacterium acnes in predicting the grouping of tumor mucosa and normal mucosa.
[0051] Fig. 9 This is a graph showing the ROC curve analysis to verify the performance of intestinal mucosal microorganism Acinetobacter pittii in predicting the grouping of tumor mucosa and normal mucosa.
[0052] Fig.10 This is a graph showing the ROC curve analysis to verify the performance of the intestinal mucosal microorganism Bacteroides uniformis in predicting the grouping of tumor mucosa and normal mucosa. DETAILED DESCRIPTION
[0053] The instruments used in the present invention are shown in Table 1 below:
[0054] Table 1: Instrument information
[0055]
[0056]
[0057] The experimental reagents and consumables used in the present invention are as follows
[0058] Reagents and consumables factory Anhydrous ethanol Shanghai Sinopharm Chemical Reagent Co., Ltd. RNase-free EP tube Wuxi Nice Life Sciences Co., Ltd. RNase-free Pipette Tips Axygen, USA EP tube (1.5 / 2.0mL) Axygen, USA Pipette Tips (1000 / 200 / 10μL) Axygen, USA Phosphate buffer (0.01 mol / L, pH 7.2-7.4) Beijing Solebow Biotechnology Co., Ltd. Isopropyl alcohol Sinopharm Chemical Reagent Co., Ltd. Tissue DNA Extraction Kit Tiangen Biochemical Technology (Beijing) Co., Ltd.
[0059] Example 1: Sample collection and processing
[0060] The present invention involves two groups of people whose information is as follows:
[0061] Population 1 (experimental set):
[0062] A total of 75 patients undergoing colorectal cancer surgery were recruited as the experimental group. During the operation, the tumor mucosa and adjacent normal intestinal mucosa (more than 5 cm) of the colorectal cancer patients were collected (see Table 2 for specific information of population 1). All the selected colorectal patients had not received chemotherapy, radiotherapy and neoadjuvant therapy before surgery. All the selected volunteers had not received any antibiotic treatment for at least one month and had not consumed probiotic foods such as yogurt within one month.
[0063] Table 2: Statistics of patients with colorectal cancer in population 1
[0064] feature Colorectal cancer patients (n=75) Age (mean ± SD) 64.93±12.352 Gender (male / female) 46 / 29
[0065] Population 2 (validation set):
[0066] Fifteen patients undergoing colorectal cancer surgery were recruited as a validation set. During the operation, the tumor mucosa and adjacent normal intestinal mucosa (more than 5 cm) of the colorectal cancer patients were collected (see Table 3 for specific information of population 2). All the selected colorectal patients had not received chemotherapy, radiotherapy or neoadjuvant therapy before surgery. All the selected volunteers had not received any antibiotic treatment for at least one month and had not consumed probiotic foods such as yogurt within one month.
[0067] Table 3: Statistics of CRC patients in population 2
[0068] feature Colorectal cancer patients (n=15) Age (mean ± SD) 62±15.722 Gender (male / female) 9 / 6
[0069] The intestinal mucosa sampling method involved in the present invention is as follows:
[0070] Intestinal mucosal sampling:
[0071] During sampling, surgical instruments were used to remove the tumor tissue and adjacent intestinal segments of the subjects and placed on sterile cloth. Scissors were used to cut about 1-2 cm of mucosal tissue away from the surgical margin and the primary tumor. The same method was used to cut about 1-2 cm of mucosal tissue in the intestinal segment more than 5 cm away from the tumor. The samples were collected in 2 mL sterile microcentrifuge tubes and immediately frozen and stored at -80°C for DNA extraction.
[0072] Example 2: Relationship between tumors and microbial abundance
[0073] 1. Detection of microbial abundance
[0074] (1) Intestinal mucosal DNA extraction, the specific steps are as follows:
[0075] The colorectal cancer mucosal tissue and adjacent normal intestinal mucosal tissue of colorectal patients in population 1 (the extracted samples in Example 1) frozen in a -80°C refrigerator were taken out, placed in a biosafety cabinet, thawed on ice, and 20 mg of intestinal mucosal samples were cut into 1.5 mL EP tubes and stored on ice.
[0076] Use the FastPure Cell / DNA Isolation Kit to extract bacterial DNA. The specific steps are as follows:
[0077] 1) Add 20 μL Proteinase K;
[0078] 2) Add 230 μL Buffer GA, vortex and mix thoroughly, incubate at 55°C for 15-30 min, centrifuge at 12,000 rpm (~13,400 × g) for 3 min, and transfer the supernatant to a new 1.5 ml centrifuge tube;
[0079] 3) Briefly centrifuge to remove water droplets on the inner wall of the tube cap. Add 180 μL of anhydrous ethanol, vortex and shake to mix thoroughly, and briefly centrifuge.
[0080] 4) Add all the solution obtained in the previous step to the adsorption column in the collection tube. Centrifuge at 12000rpm for 1min, pour out the waste liquid in the collection tube, and put the adsorption column back into the collection tube;
[0081] 5) Add 500 μL Washing Buffer A to the adsorption column, centrifuge at 12,000 rpm for 1 min, discard the waste liquid in the collection tube, and put the adsorption column back into the collection tube;
[0082] 6) Add 650 μL Washing Buffer B to the adsorption column, centrifuge at 12,000 rpm for 1 min, discard the waste liquid in the collection tube, and put the adsorption column back into the collection tube;
[0083] 7) Repeat the above step 6);
[0084] 8) Discard the filtrate and place the adsorption column in a collection tube. Centrifuge at 12,000 rpm for 2 minutes and discard the waste liquid in the collection tube. Place the adsorption column at room temperature for several minutes to dry thoroughly;
[0085] 9) Place the adsorption column in a new centrifuge tube, add 50 μL of Elution Buffer preheated to 70°C or sterile water to the middle of the adsorption column, place at room temperature for 2-5 minutes, centrifuge at 12000 rpm for 1 minute, collect the DNA solution, and store the DNA at -20°C.
[0086] The tumor mucosa DNA solutions and adjacent normal intestinal mucosa DNA solutions of colorectal cancer patients in population 1 sample set were prepared respectively.
[0087] (2) 2bRAD-M high-throughput sequencing
[0088] The DNA solution collected in step (1) was subjected to high-throughput sequencing, and the sequencing technology protocol was implemented at Qingdao Sino-Europe Biotechnology Co., Ltd. (Qingdao, China).
[0089] The details are as follows:
[0090] 1) Use type IIB restriction endonucleases to electronically digest the microbial genome and extract the tags of each genome;
[0091] 2) Construct a species-level unique tag database (2b-Tag-DB) based on species classification information;
[0092] 3) Compare the clean reads of the sample with the 2b-Tag-DB database for qualitative analysis;
[0093] 4) Filter false positives based on the gscore threshold and screen candidate microorganisms;
[0094] 5) Construct a unique tag database at the candidate microbial species level for each sample;
[0095] 6) Realign the clean reads to the database in step 5 for quantitative analysis.
[0096] (3) Obtain the relative abundance information of intestinal mucosal microorganisms in patients with colorectal cancer through step (2).
[0097] The relative abundance of microorganisms in tumor mucosal tissue and adjacent normal mucosal tissue was compared, and five microorganisms were found, namely Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacter pittii, and Bacteroides uniformis.
[0098] The abundance of five microorganisms in colorectal tumor mucosal tissue and normal mucosal tissue was compared. Figure 3 As shown in the figure, there were significant differences in the above five microorganisms between the tumor mucosa group and the normal mucosa group.
[0099] 2. (1) Using the relative abundance data of the five microorganisms in the intestinal mucosal microorganisms of colorectal cancer patients obtained above, a ROC curve was prepared, specifically:
[0100] First, the SPSS software was used to perform logistic regression on the relative abundance of the five microorganisms in the intestinal mucosal microorganisms of population 1 to obtain the predicted value, and the predicted value was set as the test variable, and the state variable was set to 0 and 1;
[0101] In the analysis of the tumor mucosa group and the normal mucosa group, the tumor mucosa group was set to 1, and the ROC curve was obtained using SPSS software. Figure 4 and Table 4;
[0102] Table 4: Diagnostic performance of microbial combinations in population 1 and samples (AUC: area under the ROC curve)
[0103]
[0104] The results showed that the area under the ROC curve (AUC) was 0.972, and the sensitivity was 100% and the specificity was 92.0% at the point closest to the upper left corner, which was the maximum value of the Youden index.
[0105] (2) Effect of a single microorganism:
[0106] SPSS software was used to perform logistic regression on the relative abundance of five microorganisms in the intestinal mucosal microorganisms of population 1, namely Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacter pittii, and Bacteroides uniformis, to obtain the predicted values. The predicted values were set as test variables, and the state variables were set as 0 and 1.
[0107] In the analysis of the tumor mucosa group and the normal mucosa group, the tumor mucosa group was set to 1, and the ROC curve was obtained using SPSS software. Figure 6 to Figure 10 As shown in Table 5.
[0108] Table 5: Relative abundance of individual microorganisms in population 1 and samples for diagnostic performance (AUC: area under the ROC curve)
[0109]
[0110] Example 3: Verification of the diagnostic efficacy of these five microorganisms
[0111] The specific steps are as follows:
[0112] Population 2 was selected to verify the diagnostic efficacy of these five microorganisms. The specific implementation method was the same as that in Example 2. First, a tumor mucosal DNA solution and an adjacent normal intestinal mucosal DNA solution of colorectal cancer patients in the population 2 test set were prepared. Then, the relative abundance of the five microorganisms Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacter pittii, and Bacteroides uniformis in the population 2 test set were obtained by 2bRAD-M high-throughput sequencing.
[0113] The relative abundance of the above five microorganisms was subjected to logistic regression using SPSS software to obtain the predicted value, and the predicted value was set as the test variable, and the state variable was set to 0 and 1;
[0114] In the analysis of the tumor mucosa group and the normal mucosa group, the tumor mucosa group was set to 1, and the ROC curve was obtained using SPSS software. Figure 5 and Table 6;
[0115] Table 6: Diagnostic efficacy validation of microbial combinations in population 2 and samples (AUC: area under the ROC curve)
[0116]
[0117] The results showed that the area under the ROC curve (AUC) was 93.8%, and the sensitivity and specificity were 86.7% and 86.7% respectively, closest to the upper left corner, where the Youden index had a maximum value.
[0118] Example 4: Diagnosis of tumor factors by microbial abundance composition
[0119] The specific steps are as follows:
[0120] 1. Obtaining the formula
[0121] Based on the relative abundance information of microorganisms in the experimental set (population 1), logistic regression analysis was performed in the tumor mucosa group and the normal mucosa group, and the formula was obtained:
[0122]
[0123] n=1.890-1735639.917x1-318.309x2+225.541x3+0.086x4+45.642x5;
[0124] x1~x5 are the relative abundances of Brevibacillus parabrevis, Candida glabrata, Cutibacteriumacnes, Acinetobacter pittii, and Bacteroides uniformis, respectively;
[0125] When P1>0.92, the individual to be tested is determined to be a colorectal cancer patient.
[0126] 2. Use the above formula to judge colorectal cancer
[0127] According to the above method, multiple subjects in the validation set of population 2 were tested respectively, and the tumor mucosal DNA solution of individual colorectal cancer patients was first prepared; then the relative abundance of 5 microorganisms Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacterpittii, and Bacteroides uniformis were obtained by 2bRAD-M high-throughput sequencing. The abundance of each microorganism was substituted into the formula in step 1 to diagnose the tumor. The results showed that the results obtained by the method of the present application were consistent with the pathological diagnosis results.
[0128] Example 1: The intestinal mucosal sample of patient 1 was selected, the intestinal mucosal DNA was extracted, the relative abundance of microorganisms was detected, and the formula was substituted to obtain P1=0.922, which is greater than the cutoff value of 0.920. The patient was diagnosed as a colorectal cancer patient, which is consistent with the actual situation.
[0129] Example 2: The intestinal mucosal sample of patient 2 was selected, the intestinal mucosal DNA was extracted, the relative abundance of microorganisms was detected, and the formula was substituted to obtain P1=0.963, which is greater than the cutoff value of 0.920. The patient was diagnosed as a colorectal cancer patient, which is consistent with the actual situation.
[0130] Example 3: The intestinal mucosal sample of patient 3 was selected, the intestinal mucosal DNA was extracted, the relative abundance of microorganisms was detected, and the formula was substituted to obtain P1=0.992, which is greater than the cutoff value of 0.920. The patient was diagnosed as a colorectal cancer patient, which is consistent with the actual situation.
[0131] Example 4: The intestinal mucosal sample of patient 4 was selected, the intestinal mucosal DNA was extracted, the relative abundance of microorganisms was detected, and the formula was substituted to obtain P1=0.940, which is greater than the cutoff value of 0.920. The patient was diagnosed as a colorectal cancer patient, which is consistent with the actual situation.
[0132] Example 5: The intestinal mucosal sample of patient 5 was selected, the intestinal mucosal DNA was extracted, the relative abundance of microorganisms was detected, and the result was substituted into the formula to obtain P1=0.923, which is greater than the cutoff value of 0.920. The patient was diagnosed as a colorectal cancer patient, which is consistent with the actual situation.
[0133] Example 6: The intestinal mucosal sample of patient 6 was selected, the intestinal mucosal DNA was extracted, the relative abundance of microorganisms was detected, and the formula was substituted to obtain P1=0.985, which is greater than the cutoff value of 0.920. The patient was diagnosed as a colorectal cancer patient, which is consistent with the actual situation.
[0134] Example 7: The intestinal mucosal sample of patient 7 was selected, the intestinal mucosal DNA was extracted, the relative abundance of microorganisms was detected, and the formula was substituted to obtain P1=0.999, which is greater than the cutoff value of 0.920. The patient was diagnosed as a colorectal cancer patient, which is consistent with the actual situation.
[0135] Example 8: The intestinal mucosal sample of patient 8 was selected, the intestinal mucosal DNA was extracted, the relative abundance of microorganisms was detected, and the formula was substituted to obtain P1=0.931, which is greater than the cutoff value of 0.920. The patient was diagnosed as a colorectal cancer patient, which is consistent with the actual situation.
[0136] Example 9: The intestinal mucosal sample of patient 9 was selected, the intestinal mucosal DNA was extracted, the relative abundance of microorganisms was detected, and the formula was substituted to obtain P1=0.987, which is greater than the cutoff value of 0.920. The patient was diagnosed as a colorectal cancer patient, which is consistent with the actual situation.
[0137] Example 10: The intestinal mucosal sample of patient 10 was selected, the intestinal mucosal DNA was extracted, the relative abundance of microorganisms was detected, and the formula was substituted to obtain P1=0.949, which is greater than the cutoff value of 0.920. The patient was diagnosed as a colorectal cancer patient, which is consistent with the actual situation.
[0138] Example 11: A normal intestinal mucosa sample adjacent to patient 11 was selected to extract intestinal mucosal DNA, detect the relative abundance of microorganisms, and substitute it into the formula to obtain P1=0.000501, which is less than the cutoff value of 0.920 and is judged to be normal, which is consistent with the actual situation.
[0139] Example 12: A normal intestinal mucosa sample adjacent to patient 12 was selected to extract intestinal mucosal DNA, detect the relative abundance of microorganisms, and substitute it into the formula to obtain P1=0.873, which is less than the cutoff value of 0.920 and is judged to be normal, which is consistent with the actual situation.
[0140] Example 13: A normal intestinal mucosa sample adjacent to patient 13 was selected to extract intestinal mucosal DNA, detect the relative abundance of microorganisms, and substitute it into the formula to obtain P1=0.874, which is less than the cutoff value of 0.920 and is judged to be normal, which is consistent with the actual situation.
[0141] Example 14: A normal intestinal mucosa sample adjacent to patient 14 was selected to extract intestinal mucosal DNA, detect the relative abundance of microorganisms, and substitute it into the formula to obtain P1=0.882, which is less than the cutoff value of 0.920 and is judged to be normal, which is consistent with the actual situation.
[0142] Example 15: A normal intestinal mucosa sample adjacent to patient 15 was selected to extract intestinal mucosal DNA, detect the relative abundance of microorganisms, and substitute it into the formula to obtain P1=0.001, which is less than the cutoff value of 0.920 and is judged to be normal, which is consistent with the actual situation.
[0143] Example 16: A normal intestinal mucosa sample adjacent to patient 16 was selected to extract intestinal mucosal DNA, detect the relative abundance of microorganisms, and substitute it into the formula to obtain P1=0.873, which is less than the cutoff value of 0.920 and is judged to be normal, which is consistent with the actual situation.
[0144] Example 17: A normal intestinal mucosa sample adjacent to patient 17 was selected to extract intestinal mucosal DNA, detect the relative abundance of microorganisms, and substitute it into the formula to obtain P1=0.001, which is less than the cutoff value of 0.920 and is judged to be normal, which is consistent with the actual situation.
[0145] Example 18: A normal intestinal mucosa sample adjacent to patient 18 was selected to extract intestinal mucosal DNA, detect the relative abundance of microorganisms, and substitute it into the formula to obtain P1=0.911, which is less than the cutoff value of 0.920 and is judged to be normal, which is consistent with the actual situation.
[0146] Example 19: A normal intestinal mucosa sample adjacent to patient 19 was selected to extract intestinal mucosal DNA, detect the relative abundance of microorganisms, and substitute it into the formula to obtain P1=0.884, which is less than the cutoff value of 0.920 and is judged to be normal, which is consistent with the actual situation.
[0147] Example 20: A normal intestinal mucosa sample adjacent to patient 20 was selected to extract intestinal mucosal DNA and detect the relative abundance of microorganisms. The relative abundance of microorganisms was substituted into the formula to obtain P1=0.001, which is less than the cutoff value of 0.920 and is judged to be normal, which is consistent with the actual situation.
[0148] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. Use of a microbial composition in the preparation of a product for evaluating or diagnosing colorectal cancer, characterized in that: The microbial composition comprises Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacter pittii, and Bacteroides uniformis. The product determines the abundance information of the microbial composition in the sample by detecting DNA in the sample; and evaluates or diagnoses whether an individual is a colorectal cancer patient based on the abundance information of the microorganisms.
2. The use according to claim 1, characterized in that: The following formula is used to determine whether the individual to be tested is a colorectal cancer patient: n=1.890-1735639.917x1-318.309x2+225.541x3+0.086x4+45.642x5; x1~x5 are the relative abundances of Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacter pittii, and Bacteroides uniformis, respectively; When P1>0.92, the individual to be tested is determined to be a colorectal cancer patient.
3. The use according to claim 1 or 2, characterized in that: The sample to be tested comes from the intestinal mucosal tissue of the patient; preferably, the test or evaluation includes one or more of diagnostic testing, progression monitoring and prognostic testing.
4. The use according to any one of claims 1 to 3, characterized in that: The products include but are not limited to biochips, kits, and devices for detecting or evaluating colorectal cancer.
5. The use according to claim 4, characterized in that: The biochip comprises a solid phase carrier and oligonucleotide probes fixed in order on the solid phase carrier, wherein the oligonucleotide probes specifically correspond to detecting the abundance of the microorganisms Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacterpittii and Bacteroides uniformis.
6. The use according to claim 4, characterized in that: The device comprises one or more devices for specifically detecting the abundance of the microorganisms Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacterpittii, and Bacteroides uniformis.
7. Use of a microbial composition in the preparation of a device for evaluating the progression of colorectal cancer, characterized in that: The microbial composition comprises Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacter pittii, and Bacteroides uniformis. The product determines the abundance information of the microbial composition in the sample by detecting DNA in the sample; and evaluates or diagnoses whether an individual is a colorectal cancer patient based on the abundance information of the microorganisms.
8. The use according to claim 7, characterized in that: The following formula is used to determine whether the individual to be tested is a colorectal cancer patient: n=1.890-1735639.917x1-318.309x2+225.541x3+0.086x4+45.642x5; x1~x5 are the relative abundances of Brevibacillus parabrevis, Candida glabrata, Cutibacterium acnes, Acinetobacter pittii, and Bacteroides uniformis, respectively; When P1>0.92, the individual to be tested is determined to be a colorectal cancer patient.
9. The use according to claim 7 or 8, characterized in that: The evaluation of colorectal cancer progression includes one or more of diagnosing and detecting colorectal cancer, monitoring colorectal cancer progression, and detecting colorectal cancer prognosis.
10. The use according to any one of claims 7 to 9, characterized in that: The samples to be tested come from the patient's intestinal mucosal tissue.
Citation Information
Patent Citations
Tumor marker and application thereof in preparation of colorectal cancer diagnostic kit
CN113564257A
Tumor marker and application thereof in preparation of colorectal cancer diagnostic kit
CN115466794A
Application of microbial marker in identification of sensitive skin
CN116837123A
Cited By
Ocular surface microbial marker combination for diagnosing diabetes or diabetic retinopathy and application thereof
CN120683280A
